A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Recruiting

Phase 1

Phase 2

AVB-101A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Sponsor:

AviadoBio Ltd

Code:

NCT06064890

Conditions

Frontotemporal Dementia

FTD

FTD-GRN

Dementia, Frontotemporal

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Intrathalamic AAV.PGRN administration

Intrathalamic AVB-101

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-03. This information was provided to ClinicalTrials.gov by AviadoBio Ltd on 2026-02-27.